{"id":"W4206303202","doi":"10.1016/j.healun.2022.01.002","title":"Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial","year":2022,"lang":"en","type":"article","venue":"The Journal of Heart and Lung Transplantation","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; University of Manitoba; Libin Cardiovascular Institute of Alberta; University of Alberta; University of Calgary","funders":"Janssen Pharmaceuticals; Bayer Canada; Johnson and Johnson; Bayer","keywords":"Ambrisentan; Riociguat; Medicine; Tolerability; Internal medicine; Pulmonary hypertension; Clinical endpoint; Prospective cohort study; Cardiology; Chronic thromboembolic pulmonary hypertension; Clinical trial; Endothelin receptor; Adverse effect; Bosentan","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303839,0.002132207,0.003541943,0.00032458,0.0003350466,0.001408824,0.0009773015,0.001250304,0.005078996],"category_scores_gemma":[0.001010617,0.0006256165,0.00231576,0.0003513831,0.00121277,0.001384917,0.0003816696,0.004376195,0.001203286],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008257393,"about_ca_system_score_gemma":0.0007864135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006489333,"about_ca_topic_score_gemma":0.001796981,"domain_scores_codex":[0.9993852,0.0002664234,0.00002807731,0.0001335996,0.00005214374,0.0001344108],"domain_scores_gemma":[0.999267,0.0002080126,0.0001288557,0.00008850566,0.00004114678,0.0002664773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9633972,0.006550912,0.001131877,0.0005863353,0.001770478,0.00008370649,0.00004717025,0.000585606,0.00354608,0.0001823025,0.001083247,0.02103497],"study_design_scores_gemma":[0.9193571,0.07196292,0.00443735,0.00004905323,0.00134724,0.00007624506,0.00004129688,0.0007854124,0.000505254,0.0002222949,0.001179869,0.00003591372],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826386,0.009372947,0.000747074,0.0006909008,0.0006695553,0.001379934,0.001234655,0.0001423179,0.003123973],"genre_scores_gemma":[0.9859896,0.004290178,0.001325664,0.00122632,0.0006469295,0.001461467,0.001920118,0.00003345436,0.003106335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005078996,"threshold_uncertainty_score":0.01699096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04113841488979578,"score_gpt":0.3255835114807127,"score_spread":0.284445096590917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}